1
|
Terzi MY, Okuyan HM, Karaboğa İ, Gökdemir CE, Tap D, Kalacı A. Urotensin-II Prevents Cartilage Degeneration in a Monosodium Iodoacetate-Induced Rat Model of Osteoarthritis. Int J Pept Res Ther 2022. [DOI: 10.1007/s10989-022-10448-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
2
|
Nassour H, Iddir M, Chatenet D. Towards Targeting the Urotensinergic System: Overview and Challenges. Trends Pharmacol Sci 2019; 40:725-734. [DOI: 10.1016/j.tips.2019.08.005] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2019] [Revised: 08/11/2019] [Accepted: 08/13/2019] [Indexed: 12/19/2022]
|
3
|
Eyre HJ, Speight T, Glazier JD, Smith DM, Ashton N. Urotensin II in the development and progression of chronic kidney disease following ⅚ nephrectomy in the rat. Exp Physiol 2019; 104:421-433. [PMID: 30575177 PMCID: PMC6492238 DOI: 10.1113/ep087366] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2018] [Accepted: 12/17/2018] [Indexed: 12/16/2022]
Abstract
NEW FINDINGS What is the central question of this study? Urotensin II is upregulated in patients in the later stages of chronic kidney disease (CKD), particularly in individuals requiring dialysis. Could treatment with a urotensin II receptor antagonist slow progression of renal disease? What is the main finding and its importance? In the rat, expression of urotensin II and its receptor increased, extending into cortical structures as CKD progressed towards end-stage renal failure. Subchronic treatment with a urotensin receptor antagonist slowed but did not prevent progression of CKD. This suggests that urotensin II contributes to the decline in renal function in CKD. ABSTRACT Elevated serum and urine urotensin II (UII) concentrations have been reported in patients with end-stage chronic kidney disease (CKD). Similar increases in UII and its receptor, UT, have been reported in animal models of CKD, but only at much earlier stages of renal dysfunction. The aim of this study was to characterize urotensin system expression as renal disease progresses to end-stage failure in a ⅚ subtotal nephrectomy (SNx) rat model. Male Sprague-Dawley rats underwent SNx or sham surgery and were killed at 8 weeks postsurgery [early (E)] or immediately before end-stage renal failure [30 ± 3 weeks postsurgery; late (L)]. Systolic blood pressure, urinary albumin:creatinine ratio and glomerulosclerosis index were all increased in SNx-E rats compared with sham-E by 8 weeks postsurgery. These changes were associated with an increase in renal immunoreactive UII staining but little change in UT expression. As CKD progressed to end-stage disease in the SNx-L group, markers of renal function deteriorated further, in association with a marked increase in immunoreactive UII and UT staining. Subchronic administration of a UT antagonist, SB-611812, at 30 mg kg-1 day-1 for 13 weeks, in a separate group of SNx rats resulted in a 2 week delay in the increase in both systolic blood pressure and urinary albumin:creatinine ratio observed in vehicle-treated SNx but did not prevent the progression of renal dysfunction. The urotensin system is upregulated as renal function deteriorates in the rat; UT antagonism can slow but not prevent disease progression, suggesting that UII plays a role in CKD.
Collapse
Affiliation(s)
- Heather J Eyre
- Divison of Pharmacy and Optometry, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
| | - Thomas Speight
- Maternal and Fetal Health Research Centre, Division of Developmental Biology and Medicine, University of Manchester, St Mary's Hospital, Manchester, UK
| | - Jocelyn D Glazier
- Maternal and Fetal Health Research Centre, Division of Developmental Biology and Medicine, University of Manchester, St Mary's Hospital, Manchester, UK
| | - David M Smith
- Discovery Sciences, Innovative Medicines & Early Development Biotech Unit, AstraZeneca, Cambridge Science Park, Cambridge, UK
| | - Nick Ashton
- Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
| |
Collapse
|
4
|
Sun SL, Liu LM. Urotensin II: an inflammatory cytokine. J Endocrinol 2019; 240:JOE-18-0505.R2. [PMID: 30601760 DOI: 10.1530/joe-18-0505] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/28/2018] [Accepted: 01/02/2019] [Indexed: 12/12/2022]
Abstract
Urotensin II (UII) is a polypeptide molecule with neurohormone-like activity. It has been confirmed that UII is widely distributed in numerous organs of different animal species from fish to mammals, including humans. The UII receptor is orphan G-protein coupled receptor 14, also known as UT. The tissue distribution of UII and UT is highly consistent, and their expression may be regulated by autocrine and paracrine mechanisms. In the body, UII has many physiological and pathophysiological activities, such as vasoconstrictor and vasodilatory actions, cell proliferation, pro-fibrosis, neuroendocrine activity, insulin resistance, and carcinogenic and inflammatory effects, which have been recognized only in recent years. In fact, UII is involved in the process of inflammatory injury and plays a key role in the onset and development of inflammatory diseases. In this paper, we will review the roles UII plays in inflammatory diseases.
Collapse
Affiliation(s)
- Sui-Lin Sun
- S Sun, Department of Infection, Second Affiliated Hospital of Nanchang University, Nanchang 330006, China, Nanchang, China
| | - Liang-Ming Liu
- L Liu, Department of Infection, Songjiang Hospital Affiliated to First People's Hospital, Shanghai Jiaotong University, Shanghai, 201600, China
| |
Collapse
|
5
|
Ugan RA, Cadirci E, Halici Z, Toktay E, Cinar I. The role of urotensin-II and its receptors in sepsis-induced lung injury under diabetic conditions. Eur J Pharmacol 2018; 818:457-469. [DOI: 10.1016/j.ejphar.2017.11.011] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2017] [Revised: 11/06/2017] [Accepted: 11/09/2017] [Indexed: 02/07/2023]
|
6
|
Chen S, Wang Y, Wan Y. Urotensin II enhances transforming growth factor-β1 expression and secretion in the kidney during aristolochic acid nephropathy. Mol Med Rep 2017; 16:6904-6909. [DOI: 10.3892/mmr.2017.7424] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2016] [Accepted: 05/12/2017] [Indexed: 11/05/2022] Open
|
7
|
Pehlivan Y, Yolbas S, Cetin GY, Alibaz-Oner F, Cagatay Y, Yilmaz N, Oztuzcu S, Donmez S, Ozgen M, Koca SS, Pamuk ON, Sayarlıoglu M, Kisacik B, Direskeneli H, Demiryurek AT, Onat AM. Investigation of the association between Rho/Rho-kinase gene polymorphisms and systemic sclerosis. Rheumatol Int 2015; 36:421-7. [PMID: 26615410 DOI: 10.1007/s00296-015-3400-4] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2015] [Accepted: 11/17/2015] [Indexed: 12/19/2022]
Abstract
Systemic sclerosis (SSc) is a disease characterized by inflammation, vascular abnormalities and fibrosis. The role of Rho/Rho-kinase pathway was demonstrated in the pathogenesis of fibrosis, inflammation and vascular abnormalities. This study was aimed to investigate the relation between SSc and Rho/Rho-kinase gene polymorphisms. The study included 339 patients with SSc and 302 healthy subjects who were apparently healthy and at similar age and gender. Genotype distributions and allele frequencies were detected by using Chi-square test or Fisher's exact Chi-square test between groups, and the haplotype analysis was applied using online program (SHEsis). Significant association was found in a polymorphism in the ROCK1 gene (rs35996865), a polymorphism in ROCK2 gene (rs10178332), a polymorphism in RhoA gene (rs2177268) and two polymorphisms in RhoC gene (rs11102522 and rs11538960) with SSc disease (p < 0.0022). In this study, association between SSc disease and Rho/Rho-kinase gene polymorphisms was investigated for the first time; significant associations between ROCK1, ROCK2, RhoA and RhoC gene polymorphisms and SSc disease were demonstrated. The results strongly suggest that this SNP may be an important risk factor for development of SSc. However, further validation of these findings in an independent cohort is necessary.
Collapse
Affiliation(s)
- Yavuz Pehlivan
- Division of Rheumatology, Department of Internal Medicine, School of Medicine, Uludag University, Görükle Kampusu, 16059, Nilüfer, Bursa, Turkey.
| | - Servet Yolbas
- Department of Rheumatology, Fırat University Faculty of Medicine, Elazig, Turkey
| | - Gozde Yıldırım Cetin
- Department of Rheumatology, Kahramanmaras Sutcu Imam University Faculty of Medicine, Kahramanmaras, Turkey
| | - Fatma Alibaz-Oner
- Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey
| | - Yonca Cagatay
- Department of Rheumatology, Istanbul Bilim University Faculty of Medicine, Istanbul, Turkey
| | - Neslihan Yilmaz
- Department of Rheumatology, Istanbul Bilim University Faculty of Medicine, Istanbul, Turkey
| | - Serdar Oztuzcu
- Department of Medical Biology, Gaziantep University Faculty of Medicine, Gaziantep, Turkey
| | - Salim Donmez
- Department of Rheumatology, Trakya University Faculty of Medicine, Edirne, Turkey
| | - Metin Ozgen
- Department of Rheumatology, Ondokuz Mayıs University Faculty of Medicine, Samsun, Turkey
| | - Suleyman Serdar Koca
- Department of Rheumatology, Fırat University Faculty of Medicine, Elazig, Turkey
| | - Omer Nuri Pamuk
- Department of Rheumatology, Trakya University Faculty of Medicine, Edirne, Turkey
| | - Mehmet Sayarlıoglu
- Department of Rheumatology, Ondokuz Mayıs University Faculty of Medicine, Samsun, Turkey
| | - Bunyamin Kisacik
- Department of Rheumatology, Gaziantep University Faculty of Medicine, Gaziantep, Turkey
| | - Haner Direskeneli
- Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey
| | | | - Ahmet Mesut Onat
- Department of Rheumatology, Gaziantep University Faculty of Medicine, Gaziantep, Turkey
| |
Collapse
|
8
|
Palabiyik SS, Karakus E, Akpinar E, Halici Z, Bayir Y, Yayla M, Kose D. The Role of Urotensin Receptors in the Paracetamol-Induced Hepatotoxicity Model in Mice: Ameliorative Potential of Urotensin II Antagonist. Basic Clin Pharmacol Toxicol 2015; 118:150-9. [DOI: 10.1111/bcpt.12447] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2015] [Accepted: 07/02/2015] [Indexed: 12/13/2022]
Affiliation(s)
- Saziye S. Palabiyik
- Department of Pharmaceutical Toxicology; Faculty of Pharmacy; Ataturk University; Erzurum Turkey
| | - Emre Karakus
- Department of Pharmacology and Toxicology; Faculty of Veterinary Medicine; Ataturk University; Erzurum Turkey
| | - Erol Akpinar
- Department of Pharmacology; Faculty of Medicine; Ataturk University; Erzurum Turkey
| | - Zekai Halici
- Department of Pharmacology; Faculty of Medicine; Ataturk University; Erzurum Turkey
| | - Yasin Bayir
- Department of Biochemistry; Faculty of Pharmacy; Ataturk University; Erzurum Turkey
| | - Muhammed Yayla
- Department of Pharmacology; Faculty of Medicine; Ataturk University; Erzurum Turkey
| | - Duygu Kose
- Department of Pharmacology; Faculty of Medicine; Ataturk University; Erzurum Turkey
| |
Collapse
|
9
|
Remst DFG, Blaney Davidson EN, van der Kraan PM. Unravelling osteoarthritis-related synovial fibrosis: a step closer to solving joint stiffness. Rheumatology (Oxford) 2015; 54:1954-63. [PMID: 26175472 DOI: 10.1093/rheumatology/kev228] [Citation(s) in RCA: 79] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2014] [Indexed: 01/01/2023] Open
Abstract
Synovial fibrosis is often found in OA, contributing heavily to joint pain and joint stiffness, the main symptoms of OA. At this moment the underlying mechanism of OA-related synovial fibrosis is not known and there is no cure available. In this review we discuss factors that have been reported to be involved in synovial fibrosis. The aim of the study was to gain insight into how these factors contribute to the fibrotic process and to determine the best targets for therapy in synovial fibrosis. In this regard, the following factors are discussed: TGF-β, connective tissue growth factor, procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2, tissue inhibitor of metalloproteinase 1, A disintegrin and metalloproteinase domain 12, urotensin-II, prostaglandin F2α and hyaluronan.
Collapse
Affiliation(s)
- Dennis F G Remst
- Radboud University Medical Center, Experimental Rheumatology, Nijmegen, The Netherlands
| | | | - Peter M van der Kraan
- Radboud University Medical Center, Experimental Rheumatology, Nijmegen, The Netherlands
| |
Collapse
|
10
|
Gögebakan B, Uruc V, Ozden R, Duman IG, Yagiz AE, Okuyan HM, Aldemir O, Dogramaci Y, Kalaci A. Urotensin II (U-II), a novel cyclic peptide, possibly associated with the pathophysiology of osteoarthritis. Peptides 2014; 54:159-61. [PMID: 24468547 DOI: 10.1016/j.peptides.2014.01.010] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/23/2013] [Revised: 01/16/2014] [Accepted: 01/16/2014] [Indexed: 01/27/2023]
Abstract
Synovial fibrosis is one of the main outcomes of osteoarthritis. Some authors have reported that urotensin-II (U-II) may cause pathologic fibrosis in cardiovascular system, lung and liver. However there are no previous reports available in the literature about its relationship with the synovial fibrosis in osteoarthritis. The aim of this study was to compare the U-II levels in knee synovial fluids obtained from osteoarthritic and non-osteoarthritic patients. Two groups were created, the osteoarthritis group and non-osteoarthritic control group. The control group was consisted of patients who underwent arthroscopic surgery for other reasons than cartilage disorders. In the osteoarthritis group all patients had grade 4 primer degenerative osteoarthritis and were treated with total knee arthroplasty. Minimum 1 mL knee synovial fluids were obtained during operation. Levels of U-II were measured by using ELISA kit U-II levels were significantly higher in the osteoarthritic group than that in the control group. No correlation was found between U-II levels and age. In conclusion, the significantly high U-II levels in the knee synovial fluid of osteoarthritic patients supported our hypothesis that "U-II may be associated with the synovial fibrosis in osteoarthritis".
Collapse
Affiliation(s)
- Bülent Gögebakan
- Mustafa Kemal University, Faculty of Medicine, Department of Medical Biology, 31034 Hatay, Turkey.
| | - Vedat Uruc
- Mustafa Kemal University, Faculty of Medicine, Department of Orthopedics and Traumatology, 31034 Hatay, Turkey
| | - Raif Ozden
- Mustafa Kemal University, Faculty of Medicine, Department of Orthopedics and Traumatology, 31034 Hatay, Turkey
| | - Ibrahim Gokhan Duman
- Mustafa Kemal University, Faculty of Medicine, Department of Orthopedics and Traumatology, 31034 Hatay, Turkey
| | - Abdullah Erman Yagiz
- Mustafa Kemal University, Faculty of Medicine, Department of Physical Therapy and Rehabilitation, 31034 Hatay, Turkey
| | - Hamza Malik Okuyan
- Mustafa Kemal University, Faculty of Medicine, Department of Medical Biology, 31034 Hatay, Turkey
| | - Ozgur Aldemir
- Mustafa Kemal University, Faculty of Medicine, Department of Medical Biology, 31034 Hatay, Turkey
| | - Yunus Dogramaci
- Mustafa Kemal University, Faculty of Medicine, Department of Orthopedics and Traumatology, 31034 Hatay, Turkey
| | - Aydiner Kalaci
- Mustafa Kemal University, Faculty of Medicine, Department of Orthopedics and Traumatology, 31034 Hatay, Turkey
| |
Collapse
|
11
|
Song Y, Zhu L, Li M. Antifibrotic effects of crocetin in scleroderma fibroblasts and in bleomycin-induced sclerotic mice. Clinics (Sao Paulo) 2013; 68:1350-7. [PMID: 24212843 PMCID: PMC3798612 DOI: 10.6061/clinics/2013(10)10] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/30/2013] [Accepted: 05/16/2013] [Indexed: 11/21/2022] Open
Abstract
OBJECTIVE To investigate the antifibrotic effects of crocetin in scleroderma fibroblasts and in sclerotic mice. METHODS Skin fibroblasts that were isolated from three systemic scleroderma (SSc) patients and three healthy subjects were treated with crocetin (0.1, 1 or 10 μM). Cell proliferation was measured with an MTT assay. Alpha-smooth muscle actin was detected via an immunohistochemical method. Alpha 1 (I) procollagen (COL1A1), alpha 1 (III) procollagen (COL3A1), matrix metalloproteinase (MMP)-1 and tissue inhibitor of matrix metalloproteinase (TIMP)-1 mRNA levels were measured using real-time PCR. SSc mice were established by the subcutaneous injection of bleomycin. Crocetin (50 mg/kg/d) was injected intraperitoneally for 14 days. Dermal thickness and lung fibrosis were assessed with Masson's trichrome staining. Plasma ET-1 was detected with an enzyme-linked immunosorbent assay (ELISA). Skin and lung ET-1 and COL1A1 mRNA levels were measured via real-time PCR. RESULTS Crocetin inhibited the proliferation of SSc and normal fibroblasts, an effect that increased with crocetin concentration and incubation time. Crocetin decreased the expression of α-SMA and the levels of mRNA for COL1A1, COL3A1 and matrix metalloproteinase-1, while crocetin increased TIMP-1 mRNA levels in both SSc and normal fibroblasts. Skin and lung fibrosis was induced, and the levels of ET-1 in the plasma, skin and lungs were elevated in bleomycin-injected mice. Crocetin alleviated the thickening of the dermis and lung fibrosis; decreased COL1A1 mRNA levels in the skin and lung; and simultaneously decreased ET-1 concentrations in the plasma and ET-1 mRNA levels in the skin and lungs of the bleomycin-induced sclerotic mice, especially during the early phase (weeks 1-3). CONCLUSION Crocetin inhibits cell proliferation, differentiation and collagen production in SSc fibroblasts. Crocetin alleviates skin and lung fibrosis in a bleomycin-induced SSc mouse model, in part due to a reduction in ET-1.
Collapse
Affiliation(s)
- Yinghua Song
- Fudan University, Zhongshan Hospital, Department of Dermatology, Shanghai, China
| | | | | |
Collapse
|
12
|
Abstract
PURPOSE OF REVIEW Urotensin II (UTS2), the most potent vasoconstrictor identified thus far, is an undecapeptide hormone with a structure that is highly conserved through mammalian phylogeny. In spite of its broad expression across the invertebrate and vertebrate world, the precise role of UTS2 in physiology and disease is still unknown. The first description of human UTS2 and its receptor brought initial promise of a potential therapeutic target for progressive renal disease, with vasoconstrictive and profibrotic actions within an autocrine and paracrine system and local renal generation that was upregulated with renal pathology. RECENT FINDINGS However, the last decade has not brought the successful development of new treatments first hoped for, with one small human clinical trial bearing negative results. What has become apparent is that the spectrum of actions of UTS2 is broad and often paradoxical. This ancient hormone has both vasoconstrictor and vasodilatory actions, has both profibrotic and antiapoptotic activity, as well as actions which are highly contextual on the particular vascular bed studied and on the presence or absence of superimposed disease state. SUMMARY With current development of newer UTS2 antagonists attempting to more closely replicate the ligand-receptor kinetics of UTS2 and its receptor, the focus on potential clinical applications of UTS2 inhibition has moved away from the kidney to the treatment of chronic lung and cardiovascular diseases.
Collapse
|
13
|
Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease with unknown etiology and pathogenesis. With high mortality risks, most of the IPF cases emerged after a damage of alveolar epithelium, where this situation stimulates the over expression of matrix components. Inflammatory process observed as a reaction to emerged damage. Prolidase as an iminodipeptidase significantly increased during the development of fibrosis. The aim of this study is to measure prolidase activity as a marker of treatment and diagnosis in an experimental lung fibrosis animal model. Thirty male Wistar rats randomly divided into three experimental groups, with ten rats in each group. Group 1, control group; group 2, bleomycin (BLM)-induced lung fibrosis group, and group 3, BLM-induced lung fibrosis treated with palosuran (urotensin-II receptor antagonist). For histopathology, the middle lobes of right lungs were embedded in paraffin, followed by fixation in 10 % buffered formalin, and evaluation of IPF was performed using the Ashcroft scoring method. Prolidase activity was determined by a photometric method based on the measurement of proline levels produced by prolidase. The fibrosis scores and the prolidase activity were significantly enhanced by BLM stimulation. The BLM + palosuran treatment decreased prolidase activity in group 3. There was a positive correlation between prolidase activity and fibrosis scores. Palosuran seems to be effective in the treatment of lung fibrosis, and prolidase activity can be used for the diagnosis and/or for management of the treatment. However, further clinical and experimental studies with animals and/or patients are needed to verify these conclusions.
Collapse
|